These cells were studied in the context of melanoma and researchers found differences between CD56bright CD16- and/or CD16+ NK cells with higher activation state for the CD16+ cells, higher degranulation capacity, and higher cytokine production [9,10]. This evidence concerns the gene FCGR3A and melanoma.